Citadel Advisors’s Sage Therapeutics SAGE Stock Holding History

Citadel Advisors’s Portfolio SAGE Stock Details SAGE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-10,500	Closed	-$83.5K	–	14728
2025 Q1	$83.5K	Sell	10,500 -7,700	-42%	-$56.4K	﹤0.01%	11710
2024 Q4	$98.8K	Buy	18,200 +1,400	+8%	+$8.56K	﹤0.01%	11502
2024 Q3	$121K	Sell	16,800 -21,500	-56%	-$197K	﹤0.01%	10861
2024 Q2	$416K	Buy	38,300 +16,500	+76%	+$211K	﹤0.01%	8429
2024 Q1	$409K	Sell	21,800 -12,500	-36%	-$288K	﹤0.01%	8824
2023 Q4	$743K	Sell	34,300 -38,200	-53%	-$757K	﹤0.01%	7262
2023 Q3	$1.49M	Buy	72,500 +33,000	+84%	+$953K	﹤0.01%	5774
2023 Q2	$1.86M	Buy	39,500 +19,500	+98%	+$970K	﹤0.01%	5275
2023 Q1	$839K	Sell	20,000 -16,400	-45%	-$705K	﹤0.01%	7179
2022 Q4	$1.39M	Buy	36,400 +6,300	+21%	+$241K	﹤0.01%	6188
2022 Q3	$1.18M	Sell	30,100 -20,800	-41%	-$804K	﹤0.01%	6631
2022 Q2	$1.64M	Sell	50,900 -38,900	-43%	-$1.3M	﹤0.01%	5955
2022 Q1	$2.97M	Sell	89,800 -10,000	-10%	-$376K	﹤0.01%	5208
2021 Q4	$4.25M	Sell	99,800 -45,300	-31%	-$1.9M	﹤0.01%	4628
2021 Q3	$6.43M	Sell	145,100 -199,500	-58%	-$9.15M	﹤0.01%	3840
2021 Q2	$19.6M	Buy	344,600 +201,600	+141%	+$14.3M	﹤0.01%	2106
2021 Q1	$10.7M	Buy	143,000 +71,200	+99%	+$5.84M	﹤0.01%	2866
2020 Q4	$6.21M	Buy	71,800 +7,200	+11%	+$531K	﹤0.01%	3318
2020 Q3	$3.95M	Buy	64,600 +21,500	+50%	+$1.09M	﹤0.01%	3512
2020 Q2	$1.79M	Sell	43,100 -6,600	-13%	-$240K	﹤0.01%	4773
2020 Q1	$1.43M	Sell	49,700 -108,700	-69%	-$6.29M	﹤0.01%	4712
2019 Q4	$11.4M	Sell	158,400 -19,100	-11%	-$2.35M	0.01%	2061
2019 Q3	$24.9M	Buy	177,500 +45,900	+35%	+$7.68M	0.01%	1281
2019 Q2	$24.1M	Buy	131,600 +78,700	+149%	+$13.4M	0.01%	1260
2019 Q1	$8.41M	Sell	52,900 -36,900	-41%	-$5.34M	﹤0.01%	2277
2018 Q4	$8.6M	Buy	89,800 +28,300	+46%	+$3.24M	﹤0.01%	2086
2018 Q3	$8.69M	Buy	61,500 +20,700	+51%	+$3.2M	﹤0.01%	2288
2018 Q2	$6.39M	Buy	40,800 +20,000	+96%	+$3.14M	﹤0.01%	2449
2018 Q1	$3.35M	Sell	20,800 -36,800	-64%	-$6.25M	﹤0.01%	2991
2017 Q4	$9.49M	Buy	57,600 +20,500	+55%	+$1.99M	0.01%	1791
2017 Q3	$2.31M	Buy	37,100 +8,500	+30%	+$668K	﹤0.01%	3239
2017 Q2	$2.28M	Buy	28,600 +3,300	+13%	+$239K	﹤0.01%	3005
2017 Q1	$1.8M	Buy	25,300 +8,300	+49%	+$486K	﹤0.01%	3183
2016 Q4	$868K	Sell	17,000 -3,900	-19%	-$184K	﹤0.01%	4046
2016 Q3	$962K	Buy	20,900 +5,300	+34%	+$216K	﹤0.01%	3887
2016 Q2	$470K	Buy	+15,600	New	+$520K	﹤0.01%	4569
2015 Q4	–	Sell	-500	Closed	-$21K	–	9117
2015 Q3	$21K	Sell	500 -3,000	-86%	-$185K	﹤0.01%	8127
2015 Q2	$256K	Buy	+3,500	New	+$225K	﹤0.01%	5978

Other funds holding SAGE

DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

IFP Advisors Tampa, Florida $4.82B AUM 20.19% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Citadel Advisors's SAGE Position: Q3 2025 in Review

Citadel Advisors sold out of Sage Therapeutics (SAGE) in Q3 2025, closing a stake of 178,337 shares — an estimated $1.63M sold.

Citadel Advisors first reported a position in SAGE in Q3 2014 and held it in 43 quarters. The position peaked at $87.1M in Q3 2020. 5 funds tracked by Wall St. Rank hold SAGE as of Q3 2025.

Citadel Advisors reported no remaining Sage Therapeutics position as of Q3 2025 after selling out during the quarter.
Citadel Advisors sold 178,337 Sage Therapeutics shares in Q3 2025, an estimated $1.63M.
Citadel Advisors first reported a position in Sage Therapeutics in Q3 2014 and held it in 43 quarters.
Citadel Advisors's Sage Therapeutics position peaked at $87.1M in Q3 2020.
5 funds tracked by Wall St. Rank held Sage Therapeutics as of Q3 2025.

Based on Citadel Advisors's 13F filing for Q3 2025, filed 14 Nov 2025.